A new study in the Journal of Hazardous Materials modeled benzene emissions from the top 5% of gas stoves in U.S. homes, ...

Researchers have developed an innovative dual-receptor T-cell therapy that promises safer and more effective cancer ...

Researchers from A*STAR Institute of Molecular and Cell Biology (A*STAR IMCB) and local biotechnology company Intra-ImmuSG ...

A team of researchers has found new insight into why some lung cancer patients do not benefit from tumor-infiltrating lymphocyte, or TIL therapy. Their findings may help improve future ways to deliver ...

A phase I study of a next-generation CAR T cell therapy showed a 52 percent complete remission rate for patients with relapsed/refractory lymphoma.

BioVaxys Technology and Sona Nanotech have signed an agreement to develop cancer therapeutics, utilising the DPX platform ...

BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) ("BioVaxys") and Sona Nanotech Inc. (CSE: SONA) (OTC: SNANF) ("Sona") announce today that they have entered into a Research Agreement ...

The heat for THT is delivered to tumors using infrared light that is absorbed by Sona's proprietary biocompatible Gold Nanorod technology which elicits a strong immune response. BioVaxys Technology ...

Detailed price information for Biovaxys Technology Corp (BVAXF) from The Globe and Mail including charting and trades.

BioVaxys Technology Corp. ( BioVaxys) and Sona Nanotech Inc. ( Sona) have entered a Research Agreement to develop new cancer ...

BioVaxys Technology Corp. (CSE: BIOV) (FSE: 5LB) (OTCQB: BVAXF) ("BioVaxys") and Sona Nanotech Inc. (CSE: SONA) (OTCQB: SNANF) ("Sona") announce today that they have entered into a Research Agreement ...

A new study found that the immunotherapy treatment worked against some types of cancers, allowing patients to avoid surgery ...